This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Phase 0 Unknown 18 enrolled The First Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0591CP in patients with relapsed and/or refractory multiple myeloma.

Timeline

Start: 2022-08-10
Primary completion: 2025-01-29
Completion: 2025-01-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CT0591CP	Cell therapy	—	—

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Summary

Timeline

Drugs

Indications